New Liquid Formulation Speeds Cancer Therapy Administration

Article

A new liquid drug formulation from Teva Pharmaceutical Industries Ltd. will allow some cancer patients to see their therapy administered faster.

A new liquid drug formulation from Teva Pharmaceutical Industries Ltd. will allow some cancer patients to see their therapy administered faster.

Teva’s bendamustine hydrochloride (Treanda) injections treat patients with chronic lymphocytic leukemia or indolent B-cell non-Hodgkin lymphoma that has progressed during or within 6 months of treatment with rituximab or a rituximab-containing regimen, according to a company press release.

Preparation time will be reduced for health care professionals with the drug’s new liquid formulation, which removes the step of reconstituting lyophilized powder with sterile water prior to adding the dose of medicine to the infusion bag and administering it to a patient.

“With the new liquid formulation of Treanda, we are not only building on the legacy of this important product, but also furthering Teva’s commitment to continuously improving our medicines,” said Paul Rittman, vice president and general manager of Teva Oncology, in a press release.

The most common side effects associated with Treanda included nausea, fatigue, vomiting, diarrhea, fever, and weight loss.

Related Videos
Whole psilocybin mushroom in a clear medication capsule | Image credit: Zim - stock.adobe.com
Patient suffering from atopic dermatitis -- Image credit: Nikkikii | stock.adobe.com
Image credit: Fabio Balbi | stock.adobe.com
Image credit: Melita - stock.adobe.com
Atopic dermatitis on a patient's hand -- Image credit: Ольга Тернавская | stock.adobe.com
cropped view of man performing chest compression on dummy during cpr training class - Image credit: LIGHTFIELD STUDIOS | stock.adobe.com
Medicine law concept. Judges gavel with pills | Image Credit: Iren Moroz - stock.adobe.com
Image credit: New Africa | stock.adobe.com
© 2024 MJH Life Sciences

All rights reserved.